the numbers belong to short tests
CJC-1295 dosage: amounts from people and mouse studies.
This page names the test amounts and how they were given. It doesn’t turn research numbers into a plan for you.
Human tests used one shot; mice got repeat shots
Researchers have tested CJC-1295 at only a few amounts. This page reports the 30, 60, or 90 micrograms for each kilogram used in people, without turning the numbers into advice.
A microgram is a millionth of a gram. Since the amount was tied to body weight, a heavier person received more.
The human work used one shot under the skin. One test gave 30 or 60 micrograms for each kilogram of body weight [1].
Another test gave 60 or 90 micrograms for each kilogram of body weight [3]. Researchers then watched growth hormone and insulin-like growth factor 1 in blood.
In special mice, each shot held 2 micrograms, or two millionths of a gram. The shots came every 24 hours, every 48 hours, or after a 72-hour gap [4].
Daily shots restored growth in those unusual mice. CJC-1295 still has no approved use in people.
The human tests didn't find a safe amount for ongoing use. These are facts from short tests, not directions for you.
Online amounts did not come from controlled human trials
Online plans for Modified GRF 1-29 or CJC-1295-plus-ipamorelin often list 100–300 micrograms [1]. Ipamorelin is another lab drug that tells the growth gland to act.
Controlled human trials didn't produce those fixed amounts. The human papers used 30–90 micrograms for each kilogram of body weight.
Those papers gave the amount once and watched the blood. They did not test an ongoing plan.
The short and long forms also stay in blood for very different times. One fixed plan can't fit both forms.
The online numbers are customs, not findings. They don't settle what is safe.
Human trials do not set an ongoing CJC-1295 amount
Published human pharmacokinetic studies used single subcutaneous doses of 30, 60 or 90 µg/kg [1][3]. These describe research dosing, not a human recommendation — CJC-1295 has no approved human use, and no study established an ongoing dose for healthy adults. Anyone citing a confident "correct" dose is citing convention, not controlled data.
That gap is worth sitting with, because "safe" is not really a property of a molecule in isolation. It describes who screened the person taking it, who set the protocol, and who is accountable if something goes wrong. A regimen assembled from a forum thread's fixed-microgram convention has nobody occupying any of those roles — no intake screening, no labs, no clinician's judgment behind the number, no one to call if it goes sideways.
A licensed U.S. clinician assesses each person before making a CJC-1295 prescribing decision. CJC-1295 is now prescribed as prescription-required care by Promise Peptides (mypromise.com), which serves U.S. patients only. Some requests end without a prescription, and the person's state and proposed treatment set the limits on what is offered. FDA approval does not cover a compounded preparation; clinical oversight does not close the long-term human safety gaps in the studies above.
Published research doses answer a different question from an individual prescribing decision.
CJC-1295 lab handling is not a home mixing guide
Researchers dissolved the dried peptide in germ-free water made for lab use. This is a lab fact, not a home mixing step.
Early work with the short body hormone used a vein. Later tests used shots under the skin [1].
Four changes help the peptide resist breakdown. The blood-protein hook makes the long form stay longer.
None of those facts gives a safe way to mix or use the drug. The peptide has no approved human instructions.
CJC-1295 human tests used a shot under the skin
Published CJC-1295 tests used a shot under the skin. Earlier work with the short body hormone also used a vein [1].
Both ways let researchers watch growth hormone and insulin-like growth factor 1. No government-approved package instructions say where or how often to inject it.
This page only reports how the tests were done. It doesn't tell you where to inject the drug.
The long form can remain when another shot is given
The hooked form stayed in blood about 5.8–8.1 days [1]. After several shots, insulin-like growth factor 1 stayed high for up to 28 days.
A daily shot worked best in special mice [4]. That mouse result does not mean daily use is safe for people.
Because the long form stays for days, some drug may remain when another shot is given. That buildup could add risk, but no long human test tells us how much.
The short form clears within minutes or hours. The form comparison keeps those times apart.
Your stomach breaks down a swallowed peptide
Every published CJC-1295 amount was given by a shot. Your stomach would break the peptide apart before it could work.
Most tests placed the shot under the skin. Early work with the short body hormone put it into a vein [1].
Four changes help the peptide last after it reaches blood. They don't protect the peptide from your stomach.
That is why human papers give the shot amount by body weight. No tested pill, nose spray, or skin form has human blood results.
A product that claims a pill works the same goes past published research. There isn't a human test behind that claim.
No human test found a safe amount for long use
The human tests used one 30–90 microgram amount for each kilogram of body weight. They only watched how long the drug and hormones stayed in blood [1].
Those tests weren't built to find a safe ongoing plan. The program for the longer form later stopped after a death was reported.
Public records don't prove the drug caused that death. Still, no paper gives a step-up plan or a safe long-term amount.
No long human safety study can back an ongoing plan. CJC-1295 has no approved human use.
Claims about weekly amounts or cycles go past the evidence. They aren't proven plans for you.